|
1
|
Kirn D, Martuza RL and Zwiebel J:
Replication-selective virotherapy for cancer: Biological
principles, risk management and future directions. Nat Med.
7:781–787. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Everts B and van der Poel HG:
Replication-selective oncolytic viruses in the treatment of cancer.
Cancer Gene Ther. 12:141–161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thorne SH, Hermiston T and Kirn D:
Oncolytic virotherapy: Approaches to tumor targeting and enhancing
antitumor effects. Semin Oncol. 32:537–548. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu TC, Galanis E and Kirn D: Clinical
trial results with oncolytic virotherapy: A century of promise, a
decade of progress. Nat Clin Pract Oncol. 4:101–117. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo ZS and Bartlett DL: Oncolytic viruses
as platform for multimodal cancer therapeutics: A promising land.
Cancer Gene Ther. 21:261–263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heise C, Sampson-Johannes A, Williams A,
McCormick F, Von Hoff DD and Kirn DH: ONY X-015, an E1B
gene-attenuated adenovirus, causes tumor-specific cytolysis and
antitumoral efficacy that can be augmented by standard
chemotherapeutic agents. Nat Med. 3:639–645. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Walker JR, McGeagh KG, Sundaresan P,
Jorgensen TJ, Rabkin SD and Martuza RL: Local and systemic therapy
of human prostate adenocarcinoma with the conditionally replicating
herpes simplex virus vector G207. Hum Gene Ther. 10:2237–2243.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Phuangsab A, Lorence RM, Reichard KW,
Peeples ME and Walter RJ: Newcastle disease virus therapy of human
tumor xenografts: Antitumor effects of local or systemic
administration. Cancer Lett. 172:27–36. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Puhlmann M, Gnant M, Brown CK, Alexander
HR and Bartlett DL: Thymidine kinase-deleted vaccinia virus
expressing purine nucleoside phosphorylase as a vector for
tumor-directed gene therapy. Hum Gene Ther. 10:649–657. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mastrangelo MJ, Maguire HC Jr, Eisenlohr
LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ and Lattime EC:
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in
patients with cutaneous melanoma. Cancer Gene Ther. 6:409–422.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim JH, Oh JY, Park BH, Lee DE, Kim JS,
Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, et al: Systemic armed
oncolytic and immunologic therapy for cancer with JX-594, a
targeted poxvirus expressing GM-CSF. Mol Ther. 14:361–370. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park BH, Hwang T, Liu TC, Sze DY, Kim JS,
Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, et al: Use of a targeted
oncolytic poxvirus, JX-594, in patients with refractory primary or
metastatic liver cancer: A phase I trial. Lancet Oncol. 9:533–542.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hwang TH, Moon A, Burke J, Ribas A,
Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K,
Diallo JS, et al: A mechanistic proof-of-concept clinical trial
with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in
patients with metastatic melanoma. Mol Ther. 19:1913–1922. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heo J, Reid T, Ruo L, Breitbach CJ, Rose
S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, et al: Randomized
dose-finding clinical trial of oncolytic immunotherapeutic vaccinia
JX-594 in liver cancer. Nat Med. 19:329–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thorne SH, Hwang TH, O'Gorman WE, Bartlett
DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, et al:
Rational strain selection and engineering creates a broad-spectrum,
systemically effective oncolytic poxvirus, JX-963. J Clin Invest.
117:3350–3358. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kirn DH, Wang Y, Le Boeuf F, Bell J and
Thorne SH: Targeting of interferon-beta to produce a specific,
multi-mechanistic oncolytic vaccinia virus. PLoS Med. 4:e3532007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Foloppe J, Kintz J, Futin N, Findeli A,
Cordier P, Schlesinger Y, Hoffmann C, Tosch C, Balloul JM and Erbs
P: Targeted delivery of a suicide gene to human colorectal tumors
by a conditionally replicating vaccinia virus. Gene Ther.
15:1361–1371. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Q, Yu YA, Wang E, Chen N, Danner RL,
Munson PJ, Marincola FM and Szalay AA: Eradication of solid human
breast tumors in nude mice with an intravenously injected
light-emitting oncolytic vaccinia virus. Cancer Res.
67:10038–10046. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hui X and Yutu J: The eradication of
smallpox in Shanghai, China, October 1950-July 1951. Bull World
Health Organ. 59:913–917. 1981.PubMed/NCBI
|
|
20
|
Ma B: Variolation, pioneer of modern
immunology. Zhonghua Yi Shi Za Zhi. 25:139–144. 1995.(In Chinese).
PubMed/NCBI
|
|
21
|
Henderson DA: The eradication of smallpox
- an overview of the past, present, and future. Vaccine. 29((Suppl
4)): D7–D9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jin Q, Chen L, Chen S, Huang J, Feng Z,
Yuan J, Jin D, Bai H and Hou Y: Characterization of the complete
genomic sequence of the vaccinia virus Tian Tan strain. Sci China.
27:562–567. 1997.
|
|
23
|
Fang Q, Yang L, Zhu W, Liu L, Wang H, Yu
W, Xiao G, Tien P, Zhang L and Chen Z: Host range, growth property,
and virulence of the smallpox vaccine: Vaccinia virus Tian Tan
strain. Virology. 335:242–251. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang X, Lu B, Yu W, Fang Q, Liu L, Zhuang
K, Shen T, Wang H, Tian P, Zhang L, et al: A novel
replication-competent vaccinia vector MVTT is superior to MVA for
inducing high levels of neutralizing antibody via mucosal
vaccination. PLoS One. 4:e41802009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Z, Wang S, Zhang Q, Tian M, Hou J,
Wang R, Liu C, Ji X, Liu Y and Shao Y: Deletion of C7L and K1L
genes leads to significantly decreased virulence of recombinant
vaccinia virus TianTan. PLoS One. 8:e681152013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu W, Fang Q, Zhu W, Wang H, Tien P, Zhang
L and Chen Z: One time intranasal vaccination with a modified
vaccinia Tiantan strain MVTT(ZCI) protects animals against
pathogenic viral challenge. Vaccine. 28:2088–2096. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Products NiftCoPaB: A summary report on
the selection of VG9 vaccinia virus strain which acquired in the
collaborative work of the national smallpox vaccine. Compil Commun
Vac Virus Strains (Beijing). 45–49. 1974.
|
|
28
|
Products CIoB: Comparison of
reactogenicity in experimental animals of five vaccinia virus
strains of domestic and abroad. 7:70–73. 1978.
|
|
29
|
Products CIoB: Comparison of
reactogenicity and immunogenicity in experimental animals of five
vaccinia virus strains of domestic and abroad. 4:13–19. 1978.
|
|
30
|
Zhu R, Huang W, Wen Z, Wang W, Zhou Y and
YC W: Studies on the virulence of a novel attenuated vaccinia virus
VG9 strain in animals. Zhongguo Bingdubing Zazhi. 1:183–187.
2011.
|
|
31
|
Zhu R, Huang W, Wang Y and Yu Y:
Immunogenicity of an attenuated vaccinia virus VG9 strain. Zhongguo
Shengwuzhipinxue Zazhi. 9:347–350. 2011.
|
|
32
|
O'Reilly MS, Boehm T, Shing Y, Fukai N,
Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J:
Endostatin: An endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang B, Tao W, Shi J, Tang L and Jin J:
Determination of ochratoxin A by polyclonal antibodies based
sensitive time-resolved fluoroimmunoassay. Arch Toxicol.
80:481–485. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zeh HJ and Bartlett DL: Development of a
replication-selective, oncolytic poxvirus for the treatment of
human cancers. Cancer Gene Ther. 9:1001–1012. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Buller RM, Smith GL, Cremer K, Notkins AL
and Moss B: Decreased virulence of recombinant vaccinia virus
expression vectors is associated with a thymidine kinase-negative
phenotype. Nature. 317:813–815. 1985. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gnant MF, Puhlmann M, Bartlett DL and
Alexander HR Jr: Regional versus systemic delivery of recombinant
vaccinia virus as suicide gene therapy for murine liver metastases.
Ann Surg. 230:352–361. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ramsey-Ewing A and Moss B: Restriction of
vaccinia virus replication in CHO cells occurs at the stage of
viral intermediate protein synthesis. Virology. 206:pp. 984–993.
1995, View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kan S, Wang Y, Sun L, Jia P, Qi Y, Su J,
Liu L, Yang G, Liu L, Wang Z, et al: Attenuation of vaccinia Tian
Tan strain by removal of viral TC7L-TK2L and TA35R genes. PLoS One.
7:e319792012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guo ZS, Naik A, OMalley ME, Popovic P,
Demarco R, Hu Y, Yin X, Yang S, Zeh HJ, Moss B, et al: The enhanced
tumor selectivity of an oncolytic vaccinia lacking the host range
and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. 65:9991–9998.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
De Clercq E: Cidofovir in the therapy and
short-term prophylaxis of poxvirus infections. Trends Pharmacol
Sci. 23:456–458. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wittek R: Vaccinia immune globulin:
Current policies, preparedness, and product safety and efficacy.
Int J Infect Dis. 10:193–201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Breitbach CJ, Burke J, Jonker D,
Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R,
et al: Intravenous delivery of a multi-mechanistic cancer-targeted
oncolytic poxvirus in humans. Nature. 477:99–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Evgin L, Acuna SA, Tanese de Souza C,
Marguerie M, Lemay CG, Ilkow CS, Findlay CS, Falls T, Parato KA,
Hanwell D, et al: Complement inhibition prevents oncolytic vaccinia
virus neutralization in immune humans and cynomolgus macaques. Mol
Ther. 23:1066–1076. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Thorne SH, Liang W, Sampath P, Schmidt T,
Sikorski R, Beilhack A and Contag CH: Targeting localized immune
suppression within the tumor through repeat cycles of immune
cell-oncolytic virus combination therapy. Mol Ther. 18:1698–1705.
2010. View Article : Google Scholar : PubMed/NCBI
|
